Dihexa 10mg — Vial Spec, Reconstitution Math & COA
A 10mg vial specification of Dihexa provides a standardized quantity of N-hexanoic-Tyr-Ile-6-aminohexanoic amide for high-precision laboratory assays and in vitro models. Designed for analytical chemistry, cellular signaling research, and comparative structural assays, this unit size allows research teams to prepare exact working aliquots while minimizing waste. While PX1 Research evaluates customer demand for diverse unit formats, researchers can explore our available inventory including [dihexa-capsules-10mg](/product/dihexa-capsules-10mg) and our full catalog of [all peptides](/all-peptides).
Quick answer
A 10mg vial specification of Dihexa provides a standardized quantity of N-hexanoic-Tyr-Ile-6-aminohexanoic amide for high-precision laboratory assays and in vitro models. Designed for analytical chemistry, cellular signaling research, and comparative structural assays, this unit size allows research teams to prepare exact working aliquots while minimizing waste. While PX1 Research evaluates customer demand for diverse unit formats, researchers can explore our available inventory including [dihexa-capsules-10mg](/product/dihexa-capsules-10mg) and our full catalog of [all peptides](/all-peptides).
Key takeaways
- In experimental settings, unit mass selection dictates both workflow efficiency and solvent budgeting.
- [Dihexa](/research-peptides/dihexa) is an oligopeptide derivative synthesized to possess high metabolic stability compared to native peptide sequences.
- Preparing exact working concentrations from a 10mg dry mass requirement demands precise volumetric calculations.
- Unlike highly hydrophilic, basic linear peptides, [Dihexa](/research-peptides/dihexa) features hydrophobic hexanoyl and isoleucine moieties that influence its solubility profile in aqueous media.
Overview & Catalog Availability of Dihexa 10mg
In experimental settings, unit mass selection dictates both workflow efficiency and solvent budgeting. A 10mg mass specification for Dihexa (N-hexanoic-Tyr-Ile-6-aminohexanoic amide) represents an optimal standard scale for benchtop screening, receptor-binding assays, and structural degradation studies. Researchers selecting this size typically seek to perform multi-well plate dilutions or short-term cellular exposure trials without subjecting larger batch reserves to unnecessary freeze-thaw cycles.
To ensure transparency in supply chain planning, PX1 Research clearly highlights format availability across our catalog. When investigating small molecule oligopeptides or peptidomimetic constructs, investigators can consult our lot-matched documentation via the coa page or calculate custom preparation metrics using our inline reconstitution calculator. If a specific lyophilized mass size is currently out of stock or supplied in alternate configurations—such as specialized solid-dose research formats like dihexa-capsules-10mg—our laboratory support team can provide full batch availability metrics and timeline estimates.
Molecular Properties & Preclinical Mechanism of Action
Dihexa is an oligopeptide derivative synthesized to possess high metabolic stability compared to native peptide sequences. Preclinical studies suggest that Dihexa functions primarily as a lipophilic, high-affinity ligand for Hepatocyte Growth Factor (HGF) and its receptor tyrosine kinase, c-Met. In vitro binding assays indicate that Dihexa binds to HGF with picomolar affinity, potentiating HGF-induced c-Met phosphorylation and downstream signal transduction pathways.
In cell culture models, activation of the HGF/c-Met axis by Dihexa has been observed to stimulate spinogenesis and synaptogenesis in cultured hippocampal neurons. Preclinical animal studies using rodent models of cognitive impairment indicate that Dihexa administration correlates with enhanced dendritic spine density and neuroplastic modifications. Because these mechanisms involve potent neurotrophic cascades, research interest remains focused on characterizing receptor-ligand kinetics, intracellular signaling pathway crosstalk, and structural activity relationships within preclinical neuroscience frameworks.
Reconstitution Calculations for 10mg Dihexa Vials
Preparing exact working concentrations from a 10mg dry mass requirement demands precise volumetric calculations. Depending on the assay protocol—whether running cell culture incubations or analytical HPLC standards—researchers must adjust diluent volumes to match target micromolar or millimolar concentrations.
When reconstituting a 10mg mass of Dihexa (molecular weight approximately 502.65 g/mol), addition of 1.0 mL of compatible solvent yields a stock concentration of 10.0 mg/mL, corresponding to approximately 19.89 mM. Adding 2.0 mL of solvent achieves a concentration of 5.0 mg/mL (~9.95 mM), whereas 3.0 mL yields 3.33 mg/mL (~6.63 mM). For lower working concentrations, serial dilution protocols should be executed using micro-pipettes calibrated under ISO 17025 laboratory standards. To streamline calculations across custom vial masses or non-standard diluent volumes, utilize the PX1 reconstitution calculator.
Solvent Selection & Solubility Parameters in Bench Protocols
Unlike highly hydrophilic, basic linear peptides, Dihexa features hydrophobic hexanoyl and isoleucine moieties that influence its solubility profile in aqueous media. Standard laboratory protocols often require pre-solubilization in organic or non-aqueous solvents before final dilution into physiological buffers.
In vitro protocols frequently employ dimethyl sulfoxide (DMSO) or ethanol (EtOH) as a primary solubilization vehicle for Dihexa. A initial stock standard of 10 mg/mL to 20 mg/mL is typically achieved in 100% laboratory-grade DMSO. Once fully dissolved, aliquots can be diluted into phosphate-buffered saline (PBS) or cell culture media (e.g., DMEM) to yield final working solutions with organic solvent concentrations remaining strictly below 0.1% to 0.5% v/v, thereby avoiding vehicle toxicity in cell-based assays. Researchers conducting aqueous-only preparations must account for slower dissolution rates and potential precipitation if solubility limits are exceeded.
Aliquot Planning & Handling Protocols
To preserve structural integrity and prevent degradation over repeated assay runs, reconstituted Dihexa working stocks should undergo structured aliquot planning immediately following solubilization. Repeated freeze-thaw cycles can induce peptide precipitation or amide bond hydrolysis, compromising analytical consistency.
Following initial reconstitution of a 10mg vial, the primary stock solution should be partitioned into single-use microcentrifuge tubes (e.g., 50 µL to 200 µL volumes) using sterile, low-binding polypropylene vials. Each aliquot must be labeled with the lot number, concentration, date of preparation, and primary solvent system. Primary working aliquots stored at -80°C maintain chemical stability for extended research windows, whereas aliquots intended for immediate use within 24 to 48 hours may be held at 2°C to 8°C.
Lot-Matched COA Verification & Analytical Purity Standards
Analytical rigor requires that every compound utilized in laboratory investigation be verified by transparent, lot-matched documentation. PX1 Research enforces strict quality assurance protocols, subjecting every production lot to rigorous third-party testing at accredited ISO 17025 laboratory facilities.
To confirm compound identity and purity, every batch of Dihexa undergoes High-Performance Liquid Chromatography (HPLC) to verify chromatographic purity (minimum threshold ≥98.0%) and Mass Spectrometry (MS) to confirm exact molecular mass (502.65 Da). Additionally, bacterial endotoxin testing via Chromogenic LAL assay ensures endotoxin levels remain strictly below <0.05 EU/mg. Principal investigators can download these verification reports directly from our central coa repository by cross-referencing the lot number printed on the container label.
Comparative Analysis: Dihexa vs. Related Neuroplasticity Research Compounds
In neurobiological research targeting synaptic plastic mechanisms and trophic factor modulation, researchers frequently compare Dihexa against alternative small molecules and signaling peptides. Understanding the distinct structural properties, signaling pathways, and potency ranges across these research tools informs experimental model selection.
While Dihexa targets the HGF/c-Met axis to induce spinogenesis, compounds like semax act primarily through brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrkB) signaling cascades. Similarly, researchers evaluating non-peptide neurogenic agents frequently study nsi-189, which exhibits distinct structural mechanisms targeting hippocampal neurogenesis in vitro, or noopept, an acyl-dipeptide investigated for its interactions with central cholinergic and glutamate receptor populations. Evaluating these distinct mechanistic profiles within our broader research library allows investigators to select the precise molecular probe required for their target pathway.
Packaging, Environmental Stability, and Storage Parameters
Maintaining chemical integrity from manufacture to laboratory bench requires stringent control over environmental variables such as temperature, humidity, and light exposure. Lyophilized and crystalline peptide preparations are susceptible to moisture absorption if packaging seals are compromised.
Dry powder preparations of Dihexa should be stored in original, sealed borosilicate glass vials at -20°C for short-term preservation or -80°C for long-term archival storage. Vials must be protected from direct light exposure using opaque secondary packaging. Prior to opening a cold-stored vial, allow the container to equilibrate to ambient room temperature (20°C to 25°C) for at least 30 to 60 minutes. This equilibration step prevents condensation of atmospheric moisture on the desiccated powder, which could otherwise accelerate hydrolytic degradation upon reconstitution.
Sourcing Guidelines & Bulk Procurement Strategy
Establishing a reliable supply chain for research-grade reagents is critical for multi-phase preclinical trials and longitudinal studies. Inconsistent compound quality across different synthesis lots introduces confounding variables that compromise scientific reproducibility.
PX1 Research operates domestic packaging and fulfillment infrastructure out of state-of-the-art facilities located in California and Arizona. All products undergo domestic manufacture and strict quality control before release. For academic institutions, contract research organizations (CROs), and corporate laboratories requiring scalable supply agreements or bulk lot reservations, detailed procurement workflows are available through our dedicated wholesale portal. Orders placed Monday through Friday ship same-day, ensuring research timelines remain uninterrupted.
Experimental Design Considerations for In Vitro Assays
When incorporating Dihexa into in vitro neuronal cell culture or cell-free enzymatic binding models, experimental design must account for compound stability, vehicle controls, and dose-response parameters. Establishing baseline controls is essential for isolating specific HGF/c-Met mediated responses from non-specific background signals.
Researchers should establish negative vehicle controls containing identical concentrations of DMSO or solvent system without active compound. In western blot or immunofluorescence assays evaluating c-Met autophosphorylation, typical experimental incubation times range from 15 minutes to 2 hours at 37°C. For long-term neurite outgrowth or spinogenesis assays spanning 24 to 72 hours, daily media replacements or compound replenishment protocols may be necessary to compensate for enzymatic turn-over or compound degradation in warm, aqueous culture conditions.
Frequently Asked Questions
What is the primary physical form of Dihexa 10mg supplied for research?
Dihexa is supplied as a lyophilized or crystalline dry powder in sealed borosilicate glass vials to ensure maximum structural stability during transport and storage prior to reconstitution.
What is the best solvent for dissolving a 10mg Dihexa vial?
Dihexa exhibits low aqueous solubility in pure water or standard saline. Protocols typically recommend pre-dissolving the powder in 100% laboratory-grade DMSO or ethanol to establish a concentrated stock solution, which is then diluted into aqueous buffers like PBS or cell culture media.
How do I calculate the volume needed for a specific concentration using 10mg of Dihexa?
Using a molecular weight of 502.65 g/mol, adding 1.0 mL of diluent to 10mg yields a ~19.89 mM stock. Adding 2.0 mL yields ~9.95 mM. You can utilize the PX1 reconstitution calculator to compute exact volumetric requirements for your target micromolar or millimolar assay needs.
What third-party testing verifies the quality of PX1 Dihexa lots?
Every lot undergoes independent ISO 17025 laboratory verification via HPLC (purity ≥98.0%), Mass Spectrometry (exact molecular mass confirmation), and LAL Chromogenic testing for bacterial endotoxins (<0.05 EU/mg). Certificates of Analysis are publicly accessible via our COA lookup page.
How should reconstituted Dihexa solutions be stored?
Reconstituted stock solutions should be partitioned into single-use polypropylene aliquots and stored at -80°C for long-term stability. Repeated freeze-thaw cycles must be avoided to prevent compound degradation.
What options are available if a 10mg vial size is not listed in stock?
PX1 Research regularly updates inventory based on laboratory demand. If a specific 10mg lyophilized vial is temporarily out of stock, researchers can review alternative research formats such as dihexa-capsules-10mg or contact lab support via our wholesale portal for custom lot fulfillment.
Is Dihexa approved for veterinary or clinical therapeutic use?
No. Dihexa is strictly designated as a research compound intended exclusively for laboratory, in vitro, and preclinical investigational use. It is not for human or veterinary administration, medical treatment, or therapeutic application.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.